Comparative Pharmacology
Head-to-head clinical analysis: CEFOBID versus FORTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOBID versus FORTAZ.
CEFOBID vs FORTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
None Documented
None Documented
2 hours (prolonged in hepatic impairment and neonates).
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic